Every 10-Q that Lexaria Bioscience Corp. (LEXX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LEXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEXX filings page.
Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $5.0 million for the nine months ended May 31, 2026, improved from $9.2 million a year earlier, driven mainly by lower research and development spending after completion of a prior Phase 1b trial. Revenue fell sharply to $20,000 from $531,923, reflecting expiry of a key licensing contract and reduced B2B activity as the company pivots toward pharmaceuticals.
Cash was $3.5 million with current liabilities of $0.4 million, yielding working capital of $3.7 million, supported by $6.5 million in net equity proceeds from two registered direct offerings. Management nonetheless states there is substantial doubt about the ability to continue as a going concern beyond the first quarter of fiscal 2027 without additional financing or partnerships.
The company continues to develop its DehydraTECH drug delivery platform, focusing on GLP‑1, GIP and glucagon drugs for diabetes and weight loss, and CBD for hypertension under an active FDA IND. It is running new human and animal GLP‑1 studies and exploring strategic options under an extended material transfer agreement with a pharmaceutical counterparty. Lexaria also discloses it received a Nasdaq notice for failing the $1.00 minimum bid price requirement and may need corporate actions, such as a reverse split, to maintain its listing.
Lexaria Bioscience Corp. reports lower revenue and a narrower loss while highlighting going concern risks. For the six months ended February 28, 2026, revenue fell to $20,000 from $357,923, reflecting the expiration of a key licensing contract and reduced B2B focus. Net loss attributable to shareholders improved to $3.0 million from $5.4 million as research and development spending decreased after completing a major GLP‑1 clinical trial.
Cash rose to $5.1 million with working capital of $5.6 million, largely driven by two equity financings that raised about $6.5 million in net proceeds. Despite this, accumulated deficit reached $66.5 million, and recurring losses and negative cash flows led management to state there is “substantial doubt” about the company’s ability to continue as a going concern over the next year. Management expects current cash to fund operations only through the first quarter of fiscal 2027 and plans to rely on additional equity or partnership funding.
Lexaria Bioscience Corp. reported a net loss of $1.6M for the quarter ended November 30, 2025, narrowing from $2.7M a year earlier as research and development spending declined to $671K from $2.0M. Quarterly revenue was $0, compared with $183,923 in the prior-year period, reflecting expiration of a key license and a strategic shift away from B2B product sales toward pharmaceutical applications of its DehydraTECH drug-delivery technology.
Cash rose to $4.3M from $1.8M at August 31, 2025, helped by $3.4M in net proceeds from a registered direct equity offering in September, leading to working capital of $3.9M. The company still had an accumulated deficit of $65.1M and disclosed that recurring losses and negative cash flows create substantial doubt about its ability to continue as a going concern, despite management’s expectation that current cash could fund operations into the first quarter of fiscal 2027. Subsequent to quarter-end, Lexaria raised an additional $3.0M net in a December registered direct offering with attached warrants.